Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deferiprone for improvement of COVID-19 symptoms
IRCT20180114038350N3Phase 3Completed
- Sponsor
- Kurdistan University of Medical Sciences
- Start
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, double-blind trial of deferiprone in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Kurdistan University of Medical Sciences. Primary endpoints: Improvement of COVID-19 symptoms, Duration of hospital stay and 4 more. Started May 2020; status: completed.
02
Drugs
deferiprone
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on IRCT20180114038350N3.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20180114038350N3.